Committed to your success


Experienced Investors, Strong Track Record

Trilantic Capital Partners was formed in 2009 by five founding partners, all of whom worked together at Lehman Brothers Merchant Banking (LBMB).  At LBMB, the firm’s principals created a strong track record of investing in and building first-class businesses, and established LBMB as a partner of choice for management teams, entrepreneurs and family-owned companies.  Since 1989, funds managed by Trilantic/LBMB have invested more than $7.6 billion of equity in over 80 companies.

Management Buyout

In April 2009, Trilantic Capital Partners five founding partners completed the acquisition of LBMB from the estate of Lehman Brothers with the support of Reinet Investments S.C.A., a Luxembourg securitization vehicle controlled by the Rupert family and listed on the Luxembourg Stock Exchange, who made a strategic, minority economic investment in connection with the transaction

Trilantic and Doppel

Since 2015, Doppel has been part of the private equity firm Trilantic. Trilantic holds 90% of the shares and opens up new business opportunities. Thanks to Trilantic the Company operate on a solid financial basis. Thanks to Trilantic, Doppel is going to invest more and more in high quality pharmaceutical injectables that are increasingly in demand.

Trilantic very much considers Doppel to be a strong base in the CDMO industry that can be built upon through organic growth, investment in greenfield facilities, and the acquisition of other businesses in the CDMO industry.

For a private equity fund, they have expressed a willingness to be involved with Doppel for a significant period of time, at least five to seven years, so we will have the time and support to execute substantial investment plans and expansion strategies with the goal of growing in terms of size and presence across diverse geographic regions. In 2016 Trilantic have been invested in Doppel development a budget of 13 million versus the Company’s income of about 90 million of euros.

The wide investment has been partly used for purchasing an innovative sterile gel production plant which has been a benefit for new clients. Sterile gel is a product Doppel will export all over the world with increasing margins.

So far the transition has been very smooth, as has been the adjustment of expectations for Doppel’s future, yet we have only just begun to lay our expansion plans for the coming years.